Drug intelligence / Profile preview

RPTR-3-003

Development stage: Preclinical
Lead developer: Repertoire Immune Medicines
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intratumoral

Overview

RPTR-3-003 is an investigational, preclinical-stage tolerizing vaccine being developed by Repertoire Immune Medicines in collaboration with Bristol Myers Squibb for the treatment of undisclosed autoimmune diseases. Discovered using Repertoire's proprietary DECODE T-cell receptor (TCR)-epitope discovery platform, the therapeutic is designed to selectively reset the immune system and restore immune homeostasis without causing broad immunosuppression. RPTR-3-003 utilizes an mRNA-based formulation delivered via lipid nanoparticles (LNPs) to target disease-driving epitopes and induce antigen-specific immune tolerance.

Beyond the preview

Go deeper on RPTR-3-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RPTR-3-003.

Explore the full profile